1. Pink Sheet

Pfizer, Moderna Discussing When To Drop Controls In COVID Vaccine Trials With US Government

 
• By Cathy Kelly

Crossover could happen along with the EUAs, Operation Warp Speed's Slaoui says, or when enough high-priority groups are inoculated, or maybe when the vaccines receive full BLA approval. Whatever officials and sponsors decide, it will create challenges for vaccine candidates still in development.

COVID-19 vaccine
Pfizer, Moderna Vaccines Moving Toward Release

Pfizer Inc. and Moderna, Inc. are working with the US Food and Drug Administration and the Trump Administration’s Operation Warp Speed on when they should allow placebo recipients in their COVID-19 vaccine trials to cross over to the active vaccine, Operation Warp Speed chief science officer Moncef Slaoui said during a press briefing on 18 November.

Pfizer announced completed results from its late stage vaccine trial the same day, and Slaoui noted that Moderna may make a similar announcement soon, signaling the end of their controlled...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.